Priftin en es it fr

Priftin Brand names, Priftin Analogs

Priftin Brand Names Mixture

  • No information avaliable

Priftin Chemical_Formula


Priftin RX_link

Priftin fda sheet

Priftin FDA

Priftin msds (material safety sheet)

Priftin Synthesis Reference

No information avaliable

Priftin Molecular Weight

149.618 g/mol

Priftin Melting Point

No information avaliable

Priftin H2O Solubility


Priftin State


Priftin LogP


Priftin Dosage Forms

Capsules and film-coated tablets (800 mg or 400 mg)

Priftin Indication

For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.

Priftin Pharmacology

Patients with end-stage renal disease (ESRD) retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can precipitate serum calcium resulting in ectopic calcification. When the product of serum calcium and phosphorus concentrations (Ca x P) exceeds 55 mg2/dL2, there is an increased risk that ectopic calcification will occur. Hyperphosphatemia plays a role in the development of secondary hyperparathyroidism in renal insufficiency. An increase in parathyroid hormone (PTH) levels is characteristic of patients with chronic renal failure. Increased levels of PTH can lead to osteitis fibrosa, a bone disease. A decrease in serum phosphorus may decrease serum PTH levels. Treatment of hyperphosphatemia includes reduction in dietary intake of phosphate, inhibition of intestinal phosphate absorption with phosphate binders, and removal of phosphate with dialysis. Sevelamer taken with meals has been shown to decrease serum phosphorus concentrations in patients with ESRD who are on hemodialysis. In vitro studies have shown that the capsule and tablet formulations bind phosphate to a similar extent. Sevelamer treatment also results in a lowering of low-density lipoprotein (LDL) and total serum cholesterol levels.

Priftin Absorption

Not absorbed following oral administration, however no absorption studies have been performed in patients with renal disease.

Priftin side effects and Toxicity

Sevelamer has been given to normal healthy volunteers in doses of up to 14 grams per day for eight days with no adverse effects. Sevelamer has been given in average doses up to 13 grams per day to hemodialysis patients. There are no reported overdosages of sevelamer in patients. Since sevelamer is not absorbed, the risk of systemic toxicity is low.

Priftin Patient Information

No information avaliable

Priftin Organisms Affected

Humans and other mammals